Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
about
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseStriving for optimal bronchodilation: focus on olodaterolPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDClinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifeA review of national guidelines for management of COPD in EuropeA review of nebulized drug delivery in COPDEfficacy of tiotropium-olodaterol fixed-dose combination in COPDProfile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyCost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.Long-acting muscarinic antagonists.Bronchodilators, receptors and cross-talk: Together is better?Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.When is dual bronchodilation indicated in COPD?Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.Safety of inhaled long-acting anti-muscarinic agents in COPD.Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.Fixed-Dose Combination Inhalers.Muscarinic Receptor Antagonists.Olodaterol + tiotropium bromide for the treatment of COPD.
P2860
Q24186411-DE57B475-3B13-4CE2-91B8-06418CE6500EQ26752887-F68BC780-AB50-42BC-AE97-10294FF58F88Q26778685-41BEF7F8-77C1-424C-8CF4-B8B85C4A4A83Q26801134-6C95E73E-3B1C-443C-BE6B-FB5DC5A34BDAQ28072014-9D8516E9-1B2A-41C4-AE85-F7CE4633B2AAQ28075295-34F7F7D9-F926-47AE-A05B-A018B17CA279Q28075367-27BE7FAA-11F3-49DF-BA58-BA1591752EF3Q35766346-C85ACB0E-1620-490F-B2CF-7304F3C22D13Q36036894-BC75EAB3-87AE-4183-AC32-2ACF8E4E61C0Q37283438-62F67538-F746-4E3C-A2A3-4483F421517AQ37468663-6AD32A32-7650-415D-81AF-E4059C4ABBC9Q38537326-7061ED44-2863-41C4-AFCD-E33346C44111Q38570698-ECD058FE-2FCF-4912-BDC8-EFC4843A464BQ38570714-4AC01AD3-1AC0-4042-BEE5-26C2D1082710Q38639661-7413A461-17C3-49A2-8940-8C3A6938254CQ38641441-60520D1F-F4D7-446A-99D2-C4CF8B96D9AEQ38754002-32BD31C6-63F6-468C-B028-A4618736BED7Q38947859-A618DCAC-BD94-435A-BB53-42302A9EB27AQ39037235-F01C0BEB-4DC8-45D2-B453-6E82F8493F72Q39232425-8DC6C8C8-412C-4F38-85DF-AD122935C42BQ40878292-F71ABD6C-A7F4-47BF-B5D3-DE34A4267916Q41018618-3E8A9932-E7B7-429D-9D22-0852DF8756A2Q47122143-5C7ACA67-B7EC-4C6E-B2C0-2DC803D46A2EQ47159721-5484D4FD-D474-40F3-B2BD-F638C0D1C90EQ47657304-C351FC8E-105D-451E-B40F-ABB361956EA2Q47966525-CE3C8450-27E0-44AA-A503-290FFF761454Q51122644-8FD4B2F7-B4E2-41FF-AE55-5D7E55D4A08FQ51432583-D83B1646-579C-4F1C-9AC4-DB90BCC48FC9Q51545895-4BCE800C-1E1F-4BE0-8AF4-D0CFB16184D4
P2860
Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of combini ...... nd, active-controlled studies.
@ast
Efficacy and safety of combini ...... nd, active-controlled studies.
@en
Efficacy and safety of combini ...... nd, active-controlled studies.
@nl
type
label
Efficacy and safety of combini ...... nd, active-controlled studies.
@ast
Efficacy and safety of combini ...... nd, active-controlled studies.
@en
Efficacy and safety of combini ...... nd, active-controlled studies.
@nl
prefLabel
Efficacy and safety of combini ...... nd, active-controlled studies.
@ast
Efficacy and safety of combini ...... nd, active-controlled studies.
@en
Efficacy and safety of combini ...... nd, active-controlled studies.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of combini ...... nd, active-controlled studies.
@en
P2093
Gemzel Hernandez
Lisa Allen
Naitee Ting
Richard ZuWallack
Roger Abrahams
P2860
P304
P356
10.2147/COPD.S72482
P407
P577
2014-10-14T00:00:00Z